Cargando…
Stereotactic Body Radiation Therapy Reirradiation for Locally Recurrent Rectal Cancer: Outcomes and Toxicity
PURPOSE: Stereotactic body radiation therapy (SBRT) has emerged as a potential therapeutic option for locally recurrent rectal cancer (LRRC) but contemporaneous clinical data are limited. We aimed to evaluate the local control, toxicity, and survival outcomes in a cohort of patients previously treat...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7718547/ https://www.ncbi.nlm.nih.gov/pubmed/33305093 http://dx.doi.org/10.1016/j.adro.2020.07.017 |
_version_ | 1783619513481166848 |
---|---|
author | Smith, Thomas O’Cathail, Sean M. Silverman, Sabrina Robinson, Maxwell Tsang, Yatman Harrison, Mark Hawkins, Maria A. |
author_facet | Smith, Thomas O’Cathail, Sean M. Silverman, Sabrina Robinson, Maxwell Tsang, Yatman Harrison, Mark Hawkins, Maria A. |
author_sort | Smith, Thomas |
collection | PubMed |
description | PURPOSE: Stereotactic body radiation therapy (SBRT) has emerged as a potential therapeutic option for locally recurrent rectal cancer (LRRC) but contemporaneous clinical data are limited. We aimed to evaluate the local control, toxicity, and survival outcomes in a cohort of patients previously treated with neoadjuvant pelvic radiation therapy for nonmetastatic locally recurrent rectal cancer, now treated with SBRT. METHODS AND MATERIALS: Inoperable rectal cancer patients with ≤3 sites of pelvic recurrence and >6 months since prior pelvic radiation therapy were identified from a prospective registry over 4 years. SBRT dose was 30 Gy in 5 fractions, daily or alternate days, using cumulative organ at risk dose constraints. Primary outcome was local control (LC). Secondary outcomes were progression free survival, overall survival, toxicity, and patient reported quality of life scores using the EQ visual analog scale (EQ-VAS) tool. RESULTS: Thirty patients (35 targets) were included. Median gross tumor volume size was 14.3 cm(3). In addition, 27 of 30 (90%) previously received 45 to 50.4 Gy in 25 of 28 fractions, with 10% receiving an alternative prescription. All patients received the planned reirradiation SBRT dose. The median follow-up was 24.5 months (interquartile range, 17.8-28.8). The 1-year LC was 84.9% (95% confidence interval [CI], 70.6-99) and a 2-year LC was 69% (95% CI, 51.8-91.9). The median progression free survival was 12.1 months (95% CI, 8.6-17.66), and median overall survival was 28.3 months (95% CI, 17.88-39.5 months). No patient experienced >G2 acute toxicity and only 1 patient experienced late G3 toxicity. Patient-reported QoL outcomes were improved at 3 months after SBRT (Δ EQ-VAS, +10 points, Wilcoxon signed-rank, P = .009). CONCLUSIONS: Our study demonstrates that, for small volume pelvic disease relapses from rectal cancer, reirradiation with 30 Gy in 5 fractions is well tolerated and achieves an excellent balance between high local control rates with limited toxicity. |
format | Online Article Text |
id | pubmed-7718547 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-77185472020-12-09 Stereotactic Body Radiation Therapy Reirradiation for Locally Recurrent Rectal Cancer: Outcomes and Toxicity Smith, Thomas O’Cathail, Sean M. Silverman, Sabrina Robinson, Maxwell Tsang, Yatman Harrison, Mark Hawkins, Maria A. Adv Radiat Oncol Scientific Article PURPOSE: Stereotactic body radiation therapy (SBRT) has emerged as a potential therapeutic option for locally recurrent rectal cancer (LRRC) but contemporaneous clinical data are limited. We aimed to evaluate the local control, toxicity, and survival outcomes in a cohort of patients previously treated with neoadjuvant pelvic radiation therapy for nonmetastatic locally recurrent rectal cancer, now treated with SBRT. METHODS AND MATERIALS: Inoperable rectal cancer patients with ≤3 sites of pelvic recurrence and >6 months since prior pelvic radiation therapy were identified from a prospective registry over 4 years. SBRT dose was 30 Gy in 5 fractions, daily or alternate days, using cumulative organ at risk dose constraints. Primary outcome was local control (LC). Secondary outcomes were progression free survival, overall survival, toxicity, and patient reported quality of life scores using the EQ visual analog scale (EQ-VAS) tool. RESULTS: Thirty patients (35 targets) were included. Median gross tumor volume size was 14.3 cm(3). In addition, 27 of 30 (90%) previously received 45 to 50.4 Gy in 25 of 28 fractions, with 10% receiving an alternative prescription. All patients received the planned reirradiation SBRT dose. The median follow-up was 24.5 months (interquartile range, 17.8-28.8). The 1-year LC was 84.9% (95% confidence interval [CI], 70.6-99) and a 2-year LC was 69% (95% CI, 51.8-91.9). The median progression free survival was 12.1 months (95% CI, 8.6-17.66), and median overall survival was 28.3 months (95% CI, 17.88-39.5 months). No patient experienced >G2 acute toxicity and only 1 patient experienced late G3 toxicity. Patient-reported QoL outcomes were improved at 3 months after SBRT (Δ EQ-VAS, +10 points, Wilcoxon signed-rank, P = .009). CONCLUSIONS: Our study demonstrates that, for small volume pelvic disease relapses from rectal cancer, reirradiation with 30 Gy in 5 fractions is well tolerated and achieves an excellent balance between high local control rates with limited toxicity. Elsevier 2020-08-07 /pmc/articles/PMC7718547/ /pubmed/33305093 http://dx.doi.org/10.1016/j.adro.2020.07.017 Text en © 2020 The Authors http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Scientific Article Smith, Thomas O’Cathail, Sean M. Silverman, Sabrina Robinson, Maxwell Tsang, Yatman Harrison, Mark Hawkins, Maria A. Stereotactic Body Radiation Therapy Reirradiation for Locally Recurrent Rectal Cancer: Outcomes and Toxicity |
title | Stereotactic Body Radiation Therapy Reirradiation for Locally Recurrent Rectal Cancer: Outcomes and Toxicity |
title_full | Stereotactic Body Radiation Therapy Reirradiation for Locally Recurrent Rectal Cancer: Outcomes and Toxicity |
title_fullStr | Stereotactic Body Radiation Therapy Reirradiation for Locally Recurrent Rectal Cancer: Outcomes and Toxicity |
title_full_unstemmed | Stereotactic Body Radiation Therapy Reirradiation for Locally Recurrent Rectal Cancer: Outcomes and Toxicity |
title_short | Stereotactic Body Radiation Therapy Reirradiation for Locally Recurrent Rectal Cancer: Outcomes and Toxicity |
title_sort | stereotactic body radiation therapy reirradiation for locally recurrent rectal cancer: outcomes and toxicity |
topic | Scientific Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7718547/ https://www.ncbi.nlm.nih.gov/pubmed/33305093 http://dx.doi.org/10.1016/j.adro.2020.07.017 |
work_keys_str_mv | AT smiththomas stereotacticbodyradiationtherapyreirradiationforlocallyrecurrentrectalcanceroutcomesandtoxicity AT ocathailseanm stereotacticbodyradiationtherapyreirradiationforlocallyrecurrentrectalcanceroutcomesandtoxicity AT silvermansabrina stereotacticbodyradiationtherapyreirradiationforlocallyrecurrentrectalcanceroutcomesandtoxicity AT robinsonmaxwell stereotacticbodyradiationtherapyreirradiationforlocallyrecurrentrectalcanceroutcomesandtoxicity AT tsangyatman stereotacticbodyradiationtherapyreirradiationforlocallyrecurrentrectalcanceroutcomesandtoxicity AT harrisonmark stereotacticbodyradiationtherapyreirradiationforlocallyrecurrentrectalcanceroutcomesandtoxicity AT hawkinsmariaa stereotacticbodyradiationtherapyreirradiationforlocallyrecurrentrectalcanceroutcomesandtoxicity |